Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7566961 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL19750968 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL19050196 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL805198 | 1.00 | GRN (0.50) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL24965929 | 0.98 | GRN (0.48) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL5275514 | 0.98 | GRN (0.48) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL15764276 | 0.94 | GRN (0.44) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL22122370 | 0.94 | GRN (0.44) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL25357322 | 0.94 | GRN (0.44) | GRNSORT1CPB2LTA4HCTSK | |
| SCHEMBL19066729 | 0.90 | GRN (0.46) | GRNSORT1CPB2CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| WO-2025070731-A1 | PEPTIDEPEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20240327461-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-0642530-B1 | DERIVATIVES OF DOLASTATIN | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1998027097-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS NEUROPROTECTIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998023599-A1 | UREA AND THIOUREA DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0832074-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997046539-A1 | AMIDE DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0767801-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5614508-A | ANTIISCHEMIC AGENTS, ALZHEIMERS, STROKE OR NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-03-25 | — | — | US | disclosed |
| WO-1996040649-A1 | AMINO ACID DERIVATIVES OF SUBSTITUTED QUINOXALINE 2,3-DIONE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996000738-A1 | ENDOTHELIN ANTAGONISTS II | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0642530-A1 | DERIVATIVES OF DOLASTATIN | BASF Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRN 3398/4885SORT1 1183/4885CPB2 512/4885 |
| US-10941182-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | GRN 1879/4885SORT1 268/4885CPB2 288/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | GRN 2487/4885SORT1 3732/4885CPB2 2599/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | GRN 1879/4885SORT1 268/4885CPB2 288/4885 |
| US-20240327461-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | GRN 1879/4885SORT1 268/4885CPB2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.